A Phase 3 interventional study of Tolvaptan and Placebo in Polycystic Kidney Disease, Autosomal Dominant, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 133 sites in 15 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-07-02.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 8 in phase 3, and was the 2nd registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2007.
This study's enrollment of 1,445 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 91 across the 18 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 18 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 16 finished, 13 (81%) have results posted.
Among the 17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd., this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2007, is one of 7 in phase 3, and was the 2nd registered.
Otsuka Holdings Co., Ltd.’s Polycystic Kidney, Autosomal Dominant studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Polycystic Kidney, Autosomal Dominant:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study's purpose is to evaluate the long-term safety and efficacy of tolvaptan versus placebo in patients with ADPKD.
This study evaluated whether or not tolvaptan is potentially beneficial, while maintaining an adequate safety profile, by reducing the rate of total kidney volume increase, while impacting the onset, severity, and progression of other important consequences of ADPKD.
During the 3-week titration phase, tolvaptan or placebo was titrated in weekly intervals from lowest to highest tolerated levels given in split-dose regimens of 45/15 mg, 60/30 mg and 90/30 mg orally upon awakening and approximately 9 hours later. As soon as a subject could not tolerate a given dose, the titration phase was over and the maintenance phase began at the dose level tolerated. The maintenance phase lasted to Month 36. Subjects were able to titrate down at any point during the study. Subjects were able to titrate up during the maintenance phase with Medical Monitor approval.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received the highest tolerated split-dose regimen (upon awakening and 9 hours later) of tolvaptan 45/15 mg, 60/30 mg, or 90/30 mg orally for 36 months.
Drug: Tolvaptan
Participants received placebo (upon awakening and 9 hours later) orally for 36 months.
Drug: Placebo
Tolvaptan was supplied as tablets.
Also known as: OPC-41061, OPC-156
Placebo was supplied as tablets.
Percentage Change Per Year in Total Kidney Volume From Baseline to Month 36
Kidney volume was assessed in T1-weighted magnetic resonance images collected at each study site and sent to a central reviewing facility. At the central reviewing facility, blinded radiologists used proprietary software to measure the volume of both kidneys.
Time frame: Baseline to Month 36
Number of ADPKD Clinical Progression Events Per 100 Follow-up Years From Baseline to Month 36
These ADPKD events in the key secondary Outcome Measure were selected on the basis of their potential relationship to progressing cystogenesis. Reducing the rate of cyst development and expansion would likely slow the progression of ADPKD. The 4 events were: (1) Onset or progression of hypertension (someone is hypertensive if they have \> 139 mmHg systolic blood pressure \[BP\], \> 89 mmHg diastolic BP, or if they are taking antihypertensive medication at any BP level); (2) severe renal pain requiring medical intervention; (3) worsening albuminuria (by category, see below); and (4) worsening renal function, defined as a 25% decrease in 1/serum creatinine from Baseline. Albuminuria was assessed using spot urine albumin/creatinine ratio measurements (all measurements in mg/mmol). Categories included normal (\< 2.8 female or \< 2.0 male), microalbuminuria (2.8-28 female or 2.0-20 male), and overt proteinuria (\> 28 female or \> 20 male.
Time frame: Baseline to Month 36
Change in Renal Function Per Year From Week 3 to Month 36
Renal function was assessed using serum creatinine measurements and was estimated using 1/serum creatinine. The formula for 1/serum creatinine is: 1/Pcr, where Pcr = serum creatinine concentration (mg/dL). The change in renal function per year was based on the slope of change, obtained by regressing renal function data against time by subject.
Time frame: Week 3 to Month 36
Change in Mean Arterial Blood Pressure Per Year in Non-hypertensive Participants From Baseline to Month 36
For participants who were non-hypertensive (systolic BP ≤ 139 mmHg and diastolic BP ≤ 89 mmHg without taking antihypertensive medications) at baseline, mean arterial blood pressure was measured at scheduled clinic visits up to the point of exposure to antihypertensive therapy for any reason. The change in mean arterial blood pressure per year was based on the slope of blood pressure, obtained by regressing blood pressure against time by subject.
Time frame: Baseline to Month 36
Area Under the Concentration-time Curve of Change in Renal Pain From Baseline to Month 36
Change from baseline in renal pain was assessed by a 0 to 10 pain scale as average area under the concentration-time curve (AUC) between baseline and the last trial visit or the last visit prior to initiating medical (eg, narcotic or anti-nociceptives \[eg, tricyclic antidepressants\]) or surgical therapy for pain. In the pain scale, score 0 represented no pain at all and score 10 represented the worst pain. A negative change score indicates less pain. AUC of renal pain was derived from renal pain scores within treatment period and was calculated using the trapezoidal rule, by dividing the number of days between the first and last assessment.
Time frame: At screening, Baseline, Day 1, every 4 months up to month 36/early tremination (ET), follow-up visit 1 and 2
Number of Hypertensive Events Per 100 Follow-up Years in Non-hypertensive Participants From Baseline to Month 36
A hypertensive event was defined as a change from non-hypertensive (systolic BP ≤ 139 mmHg and diastolic BP ≤ 89 mmHg without taking antihypertensive medications) status to 1 of 3 conditions: (1) High pre-hypertensive (systolic BP \[sBP\] \> 129 mmHg and/or diastolic BP \[dBP\] \> 84 mmHg), (2) hypertensive (sBP \> 139 mmHg and/or dBP \> 89 mmHg), or (3) requiring antihypertensive therapy.
Time frame: Baseline to Month 36
Percentage of Participants With a Clinically Sustained Decrease of Blood Pressure Leading to a Sustained Reduction in Antihypertensive Therapy From Baseline to Month 36
Time frame: Baseline to Month 36
| Milestone | Tolvaptan | Placebo |
|---|---|---|
| Started | 961 | 484 |
| Received treatment | 961 | 483 |
| Completed | 740 | 417 |
| Not completed | 221 | 67 |
| Withdrew: Lost to follow-up | 15 | 8 |
| Withdrew: Adverse event | 148 | 24 |
| Withdrew: Subject met withdrawal criteria | 4 | 0 |
| Withdrew: Investigator withdrew subject | 3 | 4 |
| Withdrew: Subject withdrew consent | 50 | 30 |
| Withdrew: Protocol deviation | 1 | 1 |
Kidney volume was assessed in T1-weighted magnetic resonance images collected at each study site and sent to a central reviewing facility. At the central reviewing facility, blinded radiologists used proprietary software to measure the volume of both kidneys.
| Percentage change per year | Tolvaptan | Placebo |
|---|---|---|
| Percentage Change Per Year in Total Kidney Volume From Baseline to Month 36 | 2.777 ± 5.659 | 5.608 ± 5.330 |
These ADPKD events in the key secondary Outcome Measure were selected on the basis of their potential relationship to progressing cystogenesis. Reducing the rate of cyst development and expansion would likely slow the progression of ADPKD. The 4 events were: (1) Onset or progression of hypertension (someone is hypertensive if they have \> 139 mmHg systolic blood pressure \[BP\], \> 89 mmHg diastolic BP, or if they are taking antihypertensive medication at any BP level); (2) severe renal pain requiring medical intervention; (3) worsening albuminuria (by category, see below); and (4) worsening renal function, defined as a 25% decrease in 1/serum creatinine from Baseline. Albuminuria was assessed using spot urine albumin/creatinine ratio measurements (all measurements in mg/mmol). Categories included normal (\< 2.8 female or \< 2.0 male), microalbuminuria (2.8-28 female or 2.0-20 male), and overt proteinuria (\> 28 female or \> 20 male.
| Events/100 follow-up years | Tolvaptan | Placebo |
|---|---|---|
| Number of ADPKD Clinical Progression Events Per 100 Follow-up Years From Baseline to Month 36 | 43.94 | 50.04 |
Renal function was assessed using serum creatinine measurements and was estimated using 1/serum creatinine. The formula for 1/serum creatinine is: 1/Pcr, where Pcr = serum creatinine concentration (mg/dL). The change in renal function per year was based on the slope of change, obtained by regressing renal function data against time by subject.
| (mg/mL)^-1 per year | Tolvaptan | Placebo |
|---|---|---|
| Change in Renal Function Per Year From Week 3 to Month 36 | -2.555 ± 9.767 | -3.682 ± 6.361 |
For participants who were non-hypertensive (systolic BP ≤ 139 mmHg and diastolic BP ≤ 89 mmHg without taking antihypertensive medications) at baseline, mean arterial blood pressure was measured at scheduled clinic visits up to the point of exposure to antihypertensive therapy for any reason. The change in mean arterial blood pressure per year was based on the slope of blood pressure, obtained by regressing blood pressure against time by subject.
| mmHg | Tolvaptan | Placebo |
|---|---|---|
| Change in Mean Arterial Blood Pressure Per Year in Non-hypertensive Participants From Baseline to Month 36 | 2.561 ± 9.798 | 2.592 ± 7.095 |
Change from baseline in renal pain was assessed by a 0 to 10 pain scale as average area under the concentration-time curve (AUC) between baseline and the last trial visit or the last visit prior to initiating medical (eg, narcotic or anti-nociceptives \[eg, tricyclic antidepressants\]) or surgical therapy for pain. In the pain scale, score 0 represented no pain at all and score 10 represented the worst pain. A negative change score indicates less pain. AUC of renal pain was derived from renal pain scores within treatment period and was calculated using the trapezoidal rule, by dividing the number of days between the first and last assessment.
| units on a scale | Tolvaptan | Placebo |
|---|---|---|
| Area Under the Concentration-time Curve of Change in Renal Pain From Baseline to Month 36 | -0.00 ± 1.29 | 0.08 ± 1.43 |
A hypertensive event was defined as a change from non-hypertensive (systolic BP ≤ 139 mmHg and diastolic BP ≤ 89 mmHg without taking antihypertensive medications) status to 1 of 3 conditions: (1) High pre-hypertensive (systolic BP \[sBP\] \> 129 mmHg and/or diastolic BP \[dBP\] \> 84 mmHg), (2) hypertensive (sBP \> 139 mmHg and/or dBP \> 89 mmHg), or (3) requiring antihypertensive therapy.
| Events/100 follow-up years | Tolvaptan | Placebo |
|---|---|---|
| Number of Hypertensive Events Per 100 Follow-up Years in Non-hypertensive Participants From Baseline to Month 36 | 31.80 | 29.60 |
| Percentage of participants | Tolvaptan | Placebo |
|---|---|---|
| Percentage of Participants With a Clinically Sustained Decrease of Blood Pressure Leading to a Sustained Reduction in Antihypertensive Therapy From Baseline to Month 36 | 6.24 | 5.62 |
Collected over Adverse events were collected from the time of signing the informed consent, throughout the 3 year treatment period and up to 42 days after the last dose of study medication. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tolvaptan | — | 177/961 (18.4%) | 793/961 (82.5%) |
| Placebo | — | 95/483 (19.7%) | 372/483 (77%) |
| Event | Tolvaptan | Placebo |
|---|---|---|
| PyelonephritisInfections and infestations | 5/961 | 5/483 |
| Alanine aminotransferase increasedInvestigations | 9/961 | 2/483 |
| Aspartate aminotransferase increasedInvestigations | 9/961 | 2/483 |
| Chest painGeneral disorders | 8/961 | 2/483 |
| AppendicitisInfections and infestations | 1/961 | 4/483 |
| Renal cyst infectionInfections and infestations | 6/961 | 4/483 |
| Renal cyst haemorrhageRenal and urinary disorders | 3/961 | 4/483 |
| Renal painRenal and urinary disorders | 1/961 | 4/483 |
| Urinary tract infectionInfections and infestations | 1/961 | 3/483 |
| NephrolithiasisRenal and urinary disorders | 2/961 | 3/483 |
| Event | Tolvaptan | Placebo |
|---|---|---|
| ThirstGeneral disorders | 532/961 | 99/483 |
| PolyuriaRenal and urinary disorders | 369/961 | 83/483 |
| HypertensionVascular disorders | 324/961 | 178/483 |
| Renal painRenal and urinary disorders | 266/961 | 172/483 |
| NocturiaRenal and urinary disorders | 281/961 | 63/483 |
| HeadacheNervous system disorders | 243/961 | 123/483 |
| PollakiuriaRenal and urinary disorders | 222/961 | 26/483 |
| NasopharyngitisInfections and infestations | 221/961 | 111/483 |
| Back painMusculoskeletal and connective tissue disorders | 138/961 | 90/483 |
| Dry mouthGastrointestinal disorders | 154/961 | 60/483 |
Intent-to-treat population: All randomized participants.
| Age, Continuous(years) | Tolvaptan | Placebo | Total |
|---|---|---|---|
| Mean | 38.6 ± 7.1 | 38.8 ± 7.1 | 38.7 ± 7.1 |
| Sex: Female, Male(Participants) | Tolvaptan | Placebo | Total |
|---|---|---|---|
| Female | 466 | 233 | 699 |
| Male | 495 | 251 | 746 |
Showing the first 100 of 133 sites across 15 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2007, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 5 years 6 months after primary completion. A results delay was requested in Feb 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Polycystic Kidney, Autosomal Dominant →
Otsuka Pharmaceutical Development & Commercialization, Inc. →